Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Drug Recalls For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Tikosyn (dofetilide) Capsules, Pfizer NDA 20-931 10/4/99 10/4/99 8/16/01 4/4/02 Tikosyn Indication: (1) Maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial blutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. (2)For the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. | Tikosyn (dofetilide) Capsules, Pfizer Inc., Labeling Revision ^ FDA's latest approval appears at the bottom of this list. ^   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | Pharma Company News © 2008 Betterchem.com